Introduction
In the last 10 years, the availability of recombinant human granulocyte colony stimulating factors (G-CSF) for hematopoietic stem cell mobilization represented a major advance in the field of allogenic stem cell transplantation (allo-SCT).
1,2 G-CSFmobilized peripheral blood stem cells (PBSC) have emerged as an attractive alternative to bone marrow (BM) as stem cell source. The first reported case of allogeneic PBSC transplantation in a patient with acute lymphocytic leukemia was published in 1989 by Kessinger et al, 3 showing clear evidence of trilineage engraftment. In 1994 and 1995, the first large series of allogeneic transplantation using PBSCs from G-CSF-mobilized donors were reported, [4] [5] [6] [7] [8] [9] [10] [11] and the use of allogeneic PBSCs as stem cell source has since rapidly grown in this setting. 12 All prospective randomized trials comparing allogeneic PBSCs to BM could confirm that the use of PBSCs is associated with faster hematological recovery. However, these studies have yielded differing results regarding the incidence of acute GVHD and chronic GVHD. 13 In an attempt to further improve the outcome after allo-SCT, several prospective clinical trials and retrospective cohort studies examining the safety and efficacy of G-CSF administration after allo-SCT have variably demonstrated beneficial effects, including reductions in time to hematopoietic recovery, transplant-related toxicity, duration of initial hospitalization, and resource utilization. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Nevertheless, the understanding of the secondary effects of G-CSF, especially on the immune system, continues to evolve. In addition to in vitro studies evaluating the impact of G-CSF on different effectors of the immune system, recent clinical data suggested that treatment with G-CSF after allo-SCT increases the risk of GVHD and transplant-related death. 33 As a matter of fact, these observations are reason for concern.
The benefit of G-CSF after allo-SCT G-CSF is sometimes used immediately after allo-SCT in an effort to hasten engraftment, thereby reducing complications and morbidities associated with neutropenia. Indeed, serious and life-threatening infectious complications after allo-SCT have been attributed to prolonged neutropenia induced by the myeloablative preparative regimen, and to neutrophil dysfunction in the early phase after transplantation. 34, 35 Therefore, in addition to their use to mobilize peripheral blood CD34 þ stem cells for autologous transplantation or in healthy donors, it is logical to evaluate hematopoietic growth factors in the early post-transplantation phase to ensure engraftment and to decrease the incidence of hazardous infectious complications. In clinical studies in the autologous transplant setting, it is now well established that administration of G-CSF after graft infusion can significantly shorten the time to neutrophil recovery, reduce days of fever or antibiotic use, and length of hospital stay. The safety and activity of G-CSF have also been evaluated in recipients of allo-SCT. In phase 1 and 2 studies, mild bone pain was the only significant toxicity noted in patients receiving the highest dose level of filgrastim. 15, 16, 36 Phase 2 studies with comparison to historical controls have suggested the beneficial effect of filgrastim or lenograstim on neutrophil recovery after allogeneic marrow transplantation. 19, 23, 24, 26, 37, 38 These results were confirmed on subset analysis of phase 3 studies of lenograstim after marrow transplantation. 20, 39 G-CSF and the pathophysiology of GVHD Given the major role of inflammatory processes in the induction of GVHD, it is obvious that the impact of G-CSF administration after allo-SCT on GVHD might represent an important matter of concern. In another word, the systematic use of G-CSF after allo-SCT might alter the risk of GVHD. In this regard, one should bear in mind that administration of G-CSF might impact other effector targets than stem cells or neutrophils. Indeed, initially it has been shown that G-CSF can stimulate hematopoietic proliferation and neutrophil differentiation, upregulate adhesion molecule expression by neutrophils, and increase neutrophil chemotaxis, phagocytosis, and intracellular killing. 40 An evergrowing body of data generated in animals and human volunteers showed that GCSF might target immune effector cells. It could decrease the production of inflammatory cytokines, 41 increase production of IL-10, 42 and promote mobilization of Th2-inducing dendritic cells 43 and Th2 immune polarization. [44] [45] [46] Advances in the understanding of the cellular and humor interactions that are intrinsic to inflammatory processes have considerably improved our knowledge and insights into the pathophysiology of GVHD. Schematically, GVHD pathophysiology can be summarized in three-step process: (i) a first phase occurring during the administration of the high-dose chemo and radiotherapy myeloablative conditioning regimen, where there is the production of inflammatory mediators and the establishment of a proinflammatory environment; (ii) a second phase where donor T lymphocytes are then activated and T-cell-target interactions can take place; (iii) a third phase where T cells may specifically kill target host cells through various mechanisms. In addition, other effectors such as NK cells, monocytes, granulocytes, and dendritic cells may be recruited or cause both specific and nonspecific tissue lesions. 47 Given the broad range of effectors that can be targeted by G-CSF, G-CSF administration after allo-SCT might impact all three phases of GVHD pathogenesis.
G-CSF and the risk of GVHD after allo-SCT
Most of the first individual studies assessing G-CSF for engraftment after allo-SCT were not powered sufficiently to test for effects on GVHD. Recently, Ho et al attempted to circumvent this difficulty, and performed a meta-analysis to determine the effect of G-CSF or GM-CSF on the risk of nonhematopoietic outcomes after allo-SCT. Data from 18 publications were analyzed in this study. These included nine prospective randomized studies, eight retrospective cohort studies, and one case-control study comprising a total of 1198 patients. The publication types were heterogeneous with regard to demographic and treatment characteristics. The pooled risk ratio estimates using growth factor was 1.08 (P ¼ 0.48) for grade II-IV acute GVHD, 1.22 (P ¼ 0.99) for grade III-IV acute GVHD, and 1.02 (P ¼ 0.86) for chronic GVHD. Thus, it was concluded that the use of hematopoietic growth factors after allo-SCT did not induce a significant change in the risk of acute or chronic GVHD, when these factors were used to shorten the initial period of neutropenia. 48 Obviously, such study has the strength of the large number of patients included, and the quality of a meta-analysis methodology, that is admitted to allow a relatively good standard of confidence level. In contradiction with the results of this meta-analysis, Remberger et al from a single center study suggested that G-CSF given after allo-SCT using HLAidentical sibling donors increases the risk of grade II-IV acute GVHD. 49 Based on a large retrospective registry study involving around 155 different transplant centers, Ringden et al studied 1789 patients with acute leukemia receiving BM transplantation and 434 patients receiving PBSC transplantation from HLAidentical siblings between 1992 and 2002. Among BM and PBSC patients, 501 (28%) and 175 (40%), respectively, were treated with G-CSF during the first 14 days after transplantation. BM or PBSC recipient patients treated with G-CSF had a faster engraftment of absolute neutrophils, but platelet engraftment was slower. In the BM group, acute GVHD grade II-IV was 50% in the G-CSF group vs 39% in the controls (RR, 1.33; Po0.007). The incidence of chronic GVHD was also increased (RR, 1.29; Po0.03). G-CSF was associated with an increase in transplantrelated mortality (RR, 1.73; Po0.00016) and had no effect on relapse, but reduced survival (RR, 0.59; Po0.0001) and leukemia-free survival rates (RR, 0.64; Po0.0003). Interestingly, no such effects of G-CSF were seen in patients receiving allogeneic PBSCs. From these results, the authors concluded that G-CSF should not be given after allo-SCT when BM is used as a stem cell source. 33 However, in a randomized pediatric study, G-CSF did not increase the risk of GVHD after BM transplantation. 50 Also, there seems to be some dispute about the deleterious impact of G-CSF in allogeneic PBSC recipients. Another study by the IBMTR in children undergoing allo-SCT for leukemia found that G-CSF post transplantation was associated with transplant-related mortality, poor survival, and poor leukemia-free survival. This study compared the results of 143 PBSC and 630 BM transplants from HLA-identical sibling donors in children and adolescents aged 8-20 years with acute leukemia. In contrast to reports in adults, treatment-related mortality (RR, 1.89; P ¼ 0.001), treatment failure (RR, 1.31; P ¼ 0.03), and mortality (RR, 1.38; P ¼ 0.01) were higher after PBSC transplantation. Risks of relapse were similar. These data suggested poorer outcomes after PBSC compared with BM transplantation in children after adjusting for relevant risk factors. Of note, PBSC transplant recipients were older, and were more likely to have advanced leukemia, but also received more frequently growth factors post-transplantation. 51 These conflicting findings add a certain level of complexity towards interpretation of the exact role of G-CSF administration after allo-SCT. One possible mechanistic explanation for the increased risk of GVHD after G-CSF administration might be related to higher levels of soluble IL-2R-alfa in patients who develop acute GVHD during administration of G-CSF than in those who developed it after the treatment had been stopped. 52 This would indirectly imply that the administration of G-CSF may aggravate acute GVHD symptoms or severity. Despite the large number of patients analyzed, it is rather intriguing that the study from Ringden et al could not identify any trend towards an adverse effect of G-CSF post transplantation in recipients of allogeneic PBSCs. To explain this apparent discrepancy, the authors advocated the immunoregulatory role mediated by several immune effectors infused with allogeneic PBSCs mobilized with G-CSF from healthy donors, in line with data showing that administration of G-CSF to recipients of T-celldepleted hematopoietic haplo-identical transplants is associated with abnormal antigen-presenting cell functions and T-cell reactivity. 53 In the latter study, elimination of postgrafting administration of G-CSF prevented immune dysregulation and accelerated functional immune recovery. 53 
Concluding remarks
At present, it is difficult to reconcile the contrasting conclusions of the above analyses. All have the strength of relatively large numbers. Nonetheless, these studies are weakened by their retrospective nature. Even more disappointing and adding another level of ambiguity, none of these studies attempted to clearly analyze the reasons for G-CSF administration, making it difficult to give entire confidence to the final conclusions. This is a key point for results interpretation, where one would question whether patients who did or did not receive G-CSF were comparable. Significant differences in patient and donor demographic characteristics, disease features, and method of GVHD prophylaxis might represent important biases. The use of a multivariate analysis to account for these imbalances, although widely admitted, might only partially eliminate the risk of confounding factors. Equally concerning is how to deal with the 'center' effect in such large retrospective studies. Indeed, surprising differences in the diagnosis of acute GVHD or even contradictory findings can be noted between centers and among clinicians within the same team. 54 Regardless of these apparent important methodological issues, we are still unsure about the effects of G-CSF administered post allo-SCT, especially in regard to their impact on GVHD incidence or severity. Therefore, fully powered randomized trials of sufficient size to address the exact effect of G-CSF on the different transplant-related issues are warranted. However, such studies would now face hesitation if proposed to potential investigators. Due to the rapid evolution of allo-SCT practice, it would be rather very difficult to obtain a homogeneous group of patients to perform such randomized studies. With the number of other crucial emerging issues yet to be addressed in the field of allo-SCT, this question may not be sufficiently high priority. The increasing use of reduced intensity conditioning regimens in replacement to myeloablative regimens would add another level of difficulties, since reduced regimens are likely modifying the natural history of GVHD after allo-SCT. 55 Given the current available conflicting data, it will remain illusive to delineate the role of G-CSF after allo-SCT. In the near future, no obvious recommendation can be formulated. While the beneficial effects of G-CSF after allogeneic BM or PBSC transplantation are likely to be very limited, if not deleterious, the introduction and wider use of other stem cell sources such as cord blood for adult patients 56, 57 will certainly emphasize the need for renewed clinical research on the impact of G-CSF after allo-SCT. At present, whenever G-CSF administration after allo-SCT appears necessary, single cases must be comprehensively assessed on an individual basis, taking into account parameters such as the number of stem cells infused with the graft and risk factors for GVHD, as for potential benefits and risks.
